• General Dermatology
  • Eczema
  • Chronic Hand Eczema
  • Alopecia
  • Aesthetics
  • Vitiligo
  • COVID-19
  • Actinic Keratosis
  • Precision Medicine and Biologics
  • Rare Disease
  • Wound Care
  • Rosacea
  • Psoriasis
  • Psoriatic Arthritis
  • Atopic Dermatitis
  • Melasma
  • NP and PA
  • Skin Cancer
  • Hidradenitis Suppurativa
  • Drug Watch
  • Pigmentary Disorders
  • Acne
  • Pediatric Dermatology
  • Practice Management
  • Prurigo Nodularis

Article

Results of Pegintron study show reduced rate of post-surgery melanoma recurrence

Rotterdam, Netherlands - Researchers here say that Pegintron, a hepatitis C drug marketed by Schering-Plough Corp., helps stop the post-surgery return of melanoma, Reuters reports.

Rotterdam, Netherlands - Researchers here say that Pegintron, a hepatitis C drug marketed by Schering-Plough Corp., helps stop the post-surgery return of melanoma, Reuters reports.

In their study, researchers at Rotterdam’s Erasmus University Medical Center found that patients who received regular injections of Pegintron following surgery to remove their tumors had a 15 percent reduced risk of cancer recurrence after four years, as compared with melanoma patients who were not administered the drug.

The phase 3 study is the final step before a company can seek approval of a drug. In March, according to Schering-Plough, based in Kenilworth, N.J., a Food and Drug Administration advisory panel postponed a review of Pegintron to treat melanoma and sought clarification of existing data. No date has been set for another review.

The Dutch study was published in the journal Lancet.

Related Videos
Benjamin Lockshin, MD, FAAD, is featured in this series.
Benjamin Lockshin, MD, FAAD, is featured in this series.
Benjamin Lockshin, MD, FAAD, is featured in this series.
1 KOL is featured in this series.
2 KOLs are featured in this series.
1 KOL is featured in this series.
2 KOLs are featured in this series.
E. James Song is featured in this video series.
E. James Song is featured in this video series.
© 2024 MJH Life Sciences

All rights reserved.